Small US drug development company Seattle Genetics put its name back on the deal making map in January 2007 when it signed two deals in close succession. The first was a collaborative agreement with fellow US company Agensys to jointly screen and select products using Seattle Genetics#8217; antibody#8211;drug conjugate (ADC) technology. The second was a US$860 M licensing deal with biotech giant Genentech for Seattle Genetics#8217; Phase I/II cancer drug SGN-40 #8211; the second time the companies have partnered this compound. Both deals are in the cancer sector and were met with great enthusiasm by the majority of Seattle Genetics#8217; investors.